Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged

Core Viewpoint - Syros Pharmaceuticals, Inc. is under investigation for potential claims related to its decision to discontinue enrollment in a key clinical trial for acute myeloid leukemia treatment, which may impact investor confidence and stock performance [1][2]. Investigation Details - On August 12, 2024, Syros announced the discontinuation of enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating a triplet regimen of tamibarotene, venetoclax, and azacitidine for newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression [2]. - The decision was based on a prespecified interim analysis indicating a low probability of demonstrating superiority at the final analysis [2]. Next Steps - Investors who purchased Syros securities and have relevant information are encouraged to assist the investigation by visiting the law firm's website or contacting their representatives [3]. Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorneys' fees if successful in recovering funds for investors [4]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors across the nation [5].